Literature DB >> 14993615

Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

Nancy S Wexler1, Judith Lorimer, Julie Porter, Fidela Gomez, Carol Moskowitz, Edith Shackell, Karen Marder, Graciela Penchaszadeh, Simone A Roberts, Javier Gayán, Denise Brocklebank, Stacey S Cherny, Lon R Cardon, Jacqueline Gray, Stephen R Dlouhy, Sandra Wiktorski, Marion E Hodes, P Michael Conneally, Jack B Penney, James Gusella, Jang-Ho Cha, Michael Irizarry, Diana Rosas, Steven Hersch, Zane Hollingsworth, Marcy MacDonald, Anne B Young, J Michael Andresen, David E Housman, Margot Mieja De Young, Ernesto Bonilla, Theresa Stillings, Americo Negrette, S Robert Snodgrass, Maria Dolores Martinez-Jaurrieta, Maria A Ramos-Arroyo, Jacqueline Bickham, Juan Sanchez Ramos, Frederick Marshall, Ira Shoulson, Gustavo J Rey, Andrew Feigin, Norman Arnheim, Amarilis Acevedo-Cruz, Leticia Acosta, Jose Alvir, Kenneth Fischbeck, Leslie M Thompson, Angela Young, Leon Dure, Christopher J O'Brien, Jane Paulsen, Adam Brickman, Denise Krch, Shelley Peery, Penelope Hogarth, Donald S Higgins, Bernhard Landwehrmeyer.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by a triplet (CAG) expansion mutation. The length of the triplet repeat is the most important factor in determining age of onset of HD, although substantial variability remains after controlling for repeat length. The Venezuelan HD kindreds encompass 18,149 individuals spanning 10 generations, 15,409 of whom are living. Of the 4,384 immortalized lymphocyte lines collected, 3,989 DNAs were genotyped for their HD alleles, representing a subset of the population at greatest genetic risk. There are 938 heterozygotes, 80 people with variably penetrant alleles, and 18 homozygotes. Analysis of the 83 kindreds that comprise the Venezuelan HD kindreds demonstrates that residual variability in age of onset has both genetic and environmental components. We created a residual age of onset phenotype from a regression analysis of the log of age of onset on repeat length. Familial correlations (correlation +/- SE) were estimated for sibling (0.40 +/- 0.09), parent-offspring (0.10 +/- 0.11), avuncular (0.07 +/- 0.11), and cousin (0.15 +/- 0.10) pairs, suggesting a familial origin for the residual variance in onset. By using a variance-components approach with all available familial relationships, the additive genetic heritability of this residual age of onset trait is 38%. A model, including shared sibling environmental effects, estimated the components of additive genetic (0.37), shared environment (0.22), and nonshared environment (0.41) variances, confirming that approximately 40% of the variance remaining in onset age is attributable to genes other than the HD gene and 60% is environmental.

Entities:  

Mesh:

Year:  2004        PMID: 14993615      PMCID: PMC373491          DOI: 10.1073/pnas.0308679101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  A general test of association for quantitative traits in nuclear families.

Authors:  G R Abecasis; L R Cardon; W O Cookson
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism.

Authors:  E P Leeflang; S Tavaré; P Marjoram; C O Neal; J Srinidhi; H MacFarlane; M E MacDonald; J F Gusella; M de Young; N S Wexler; N Arnheim
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

3.  Direct amplification of the CAG repeat of huntingtin without amplification of CCG.

Authors:  C E Bond; M E Hodes
Journal:  Clin Chem       Date:  1996-05       Impact factor: 8.327

4.  Pedigree tests of transmission disequilibrium.

Authors:  G R Abecasis; W O Cookson; L R Cardon
Journal:  Eur J Hum Genet       Date:  2000-07       Impact factor: 4.246

5.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals.

Authors:  J B Penney; A B Young; I Shoulson; S Starosta-Rubenstein; S R Snodgrass; J Sanchez-Ramos; M Ramos-Arroyo; F Gomez; G Penchaszadeh; J Alvir
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

Review 7.  Huntington's disease: the challenge for cell biologists.

Authors:  A J Tobin; E R Signer
Journal:  Trends Cell Biol       Date:  2000-12       Impact factor: 20.808

8.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.

Authors:  S E Andrew; Y P Goldberg; B Kremer; H Telenius; J Theilmann; S Adam; E Starr; F Squitieri; B Lin; M A Kalchman
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

9.  Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.

Authors:  R G Snell; J C MacMillan; J P Cheadle; I Fenton; L P Lazarou; P Davies; M E MacDonald; J F Gusella; P S Harper; D J Shaw
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

10.  Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum.

Authors:  E P Leeflang; L Zhang; S Tavaré; R Hubert; J Srinidhi; M E MacDonald; R H Myers; M de Young; N S Wexler; J F Gusella
Journal:  Hum Mol Genet       Date:  1995-09       Impact factor: 6.150

View more
  239 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

Review 3.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

4.  Genetic background modulates behavioral impairments in R6/2 mice and suggests a role for dominant genetic modifiers in Huntington’s disease pathogenesis.

Authors:  Randi-Michelle Cowin; Nghiem Bui; Deanna Graham; Jennie R Green; Lisa A Yuva-Paylor; Andreas Weiss; Richard Paylor
Journal:  Mamm Genome       Date:  2012-06       Impact factor: 2.957

Review 5.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

6.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.

Authors:  J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting
Journal:  J Pediatr       Date:  2010-06-30       Impact factor: 4.406

Review 7.  Before senescence: the evolutionary demography of ontogenesis.

Authors:  Daniel A Levitis
Journal:  Proc Biol Sci       Date:  2010-12-01       Impact factor: 5.349

8.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

9.  Assessment of cortical and striatal involvement in 523 Huntington disease brains.

Authors:  Tiffany C Hadzi; Audrey E Hendricks; Jeanne C Latourelle; Kathryn L Lunetta; L Adrienne Cupples; Tammy Gillis; Jayalakshmi Srinidhi Mysore; James F Gusella; Marcy E MacDonald; Richard H Myers; Jean-Paul Vonsattel
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

10.  A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.

Authors:  Andrew M Tidball; Miles R Bryan; Michael A Uhouse; Kevin K Kumar; Asad A Aboud; Jack E Feist; Kevin C Ess; M Diana Neely; Michael Aschner; Aaron B Bowman
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.